Nicotinic acetylcholine receptor alpha-6 beta-2 beta-3 subtype (alpha6beta2beta3 nAChR) (alpha6beta2beta3 nAChR)

The Nicotinic acetylcholine receptor alpha-6 beta-2 beta-3 subtype is a specialized heteromeric ligand-gated ion channel primarily localized in the dopaminergic neurons of the central nervous system, particularly within the nigrostriatal and mesolimbic pathways (PubMed [2, 18]). This receptor subtype is composed of alpha-6, beta-2, and beta-3 subunits, where the beta-3 subunit often acts as an accessory component essential for the proper assembly and stability of the complex (PubMed [1, 3]). It plays a pivotal role in modulating the release of dopamine in the striatum and nucleus accumbens, making it a central player in the brain's reward system and motor control (PubMed [2, 5, 9]). Due to its high sensitivity to nicotine, the alpha-6 beta-2 beta-3 subtype is heavily implicated in the pathophysiology of nicotine addiction and tobacco dependence (PubMed [1, 11, 13]). Furthermore, its selective expression on dopaminergic terminals makes it a significant target in Parkinson's disease research, as these receptors are among the first to be lost during neurodegeneration and are involved in the development of L-dopa-induced dyskinesias (PubMed [7, 9]). Therapeutic strategies targeting this receptor include the use of partial agonists for smoking cessation and the development of subtype-selective antagonists or modulators to manage motor complications in neurodegenerative disorders (PubMed [15, 18]).

Other names

CHRNA6-CHRNB2-CHRNB3 receptoralpha6-beta2-beta3 nicotinic receptorα6β2β3* nAChRalpha6* nAChRNicotinic acetylcholine receptor alpha6beta2beta3 subtype

Agonist, partial agonist, or antagonist of the pentameric ligand-gated ion channel, modulating the influx of cations such as sodium, potassium, and calcium to regulate neuronal excitability and neurotransmitter release (PubMed [11, 12, 15]).